10.1371/journal.pone.0098557.g002 Justin P. Williams Justin P. Williams Inki Kim Inki Kim Emma Ito Emma Ito Wei Shi Wei Shi Shijun Yue Shijun Yue Lillian L. Siu Lillian L. Siu John Waldron John Waldron Brian O'Sullivan Brian O'Sullivan Kenneth W. Yip Kenneth W. Yip Fei-Fei Liu Fei-Fei Liu Dacomitinib demonstrated <i>in vitro</i> efficacy in EGFR over-expressing SCCHN cell lines. Public Library of Science 2014 physiology Endocrine physiology Growth factors Epidermal growth factor oncology Cancers and neoplasms carcinomas Squamous cell carcinomas Head and neck squamous cell carcinoma Head and neck tumors Cancer treatment Radiation therapy demonstrated efficacy egfr over-expressing scchn 2014-05-22 03:33:55 Figure https://plos.figshare.com/articles/figure/_Dacomitinib_demonstrated_in_vitro_efficacy_in_EGFR_over_expressing_SCCHN_cell_lines_/1034699 <p>(A to D) Growth inhibition of three SCCHN and the NOE cell lines, treated with Dacomitinib, with or without IR. (B) FaDu; (C) UT-SCC-8; (D) UT-SCC-42a; and (E) NOE cells were treated with Dacomitinib (0, 10, 25, 50, 100, or 250 nM) alone, or in combination with IR (0, 2, or 4 Gy). MTS assays were conducted 72 hours post-treatment. The graphs represent data from 3 independent experiments, with the mean ± SEM reported. *p<0.05, **p<0.01, ***p<0.001; one-way ANOVA. No statistically significant difference between curves for Figure 2A-D; two-way ANOVA. Combination of Dacomitinib plus RT did not result in a synergistic interaction for any of the dosing regimens in all three SCCHN cell lines (Chou-Talalay Method).</p>